image credit- shutterstock
Everest Medicines, a China-based biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialisation of innovative therapeutics, has announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON.
NEFECON is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.
IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.
Taiwan region became the last region across all Everest's territories to grant full approval for NEFECON, together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON's foundational first-line cornerstone treatment for IgAN patients.
NEFECON is currently the world's first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency MHRA）in the United Kingdom , as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea.
